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Abstract
Background: This paper examines the specificity and sensitivity of a breath carbon monoxide (BCO) test and
optimum BCO cutoff level for validating self-reported tobacco smoking in Indigenous Australians in Arnhem Land,
Northern Territory (NT).
Methods: In a sample of 400 people (≥16 years) interviewed about tobacco use in three communities, both self-
reported smoking and BCO data were recorded for 309 study participants. Of these, 249 reported smoking tobacco
within the preceding 24 hours, and 60 reported they had never smoked or had not smoked tobacco for ≥6
months. The sample was opportunistically recruited using quotas to reflect age and gender balances in the
communities where the combined Indigenous populations comprised 1,104 males and 1,215 females (≥16 years).
Local Indigenous research workers assisted researchers in interviewing participants and facilitating BCO tests using
a portable hand-held analyzer.
Results: A BCO cutoff of ≥7 parts per million (ppm) provided good agreement between self-report and BCO
(96.0% sensitivity, 93.3% specificity). An alternative cutoff of ≥5 ppm increased sensitivity from 96.0% to 99.6% with
no change in specificity (93.3%). With data for two self-reported nonsmokers who also reported that they smoked
cannabis removed from the analysis, specificity increased to 96.6%.
Conclusion: In these disadvantaged Indigenous populations, where data describing smoking are few, testing for
BCO provides a practical, noninvasive, and immediate method to validate self-reported smoking. In further studies
of tobacco smoking in these populations, cannabis use should be considered where self-reported nonsmokers
show high BCO.
Introduction
Over the past two decades, smoking rates in Australia
have halved in the general population from 35% to 18%
with predictions of 14% by 2020[1]. However, for Indi-
genous Australians, smoking rates appear to have
remained unchanged. Nationally, 51% of Indigenous
men and 47% of Indigenous women report to be regular
smokers[2].Smoking rates vary across Indigenous Aus-
tralian populations. For example, much higher rates of
between 59% to 83%[3-8] have been documented in
some remote communities of the Northern Territory
(NT), with up to 92% of people reporting a history of
tobacco use in one community[3].
Indigenous Australians experience a burden of disease
2.4 times that of non-Indigenous Australians[9], with
the gap between Indigenous and non-Indigenous life
expectancy at birth in 2009 estimated to be 11.5 years
for men and 9.7 years for women[10]. About 12% of the
burden of disease[9] and 20% of indigenous deaths[11]
are attributable to tobacco use. In 2008, the Australian
government made a commitment to “closing the gap” in
Indigenous Australian life expectancy[12], including
addressing smoking[13].
Documenting tobacco use in Indigenous communities
has typically relied on self-report in surveys, with a few
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studies using biochemical markers to verify self-report.
Urine cotinine has been used in both urban[14] and
remote clinic-based studies[7]. However, this involves
the complexities and cost of obtaining and testing a
urine sample and does not provide an immediate assess-
ment of smoking. Portable, hand-held Breath Carbon
Monoxide (BCO) analyzers are tools used to immedi-
ately assess smoking status. They are suitable for both
clinical and community-based studies[15-23] and are
being used in a small number of Indigenous Australian
settings[24-26]. The utility of BCO analyzers and opti-
mum BCO cutoff to distinguish smokers and nonsmo-
kers is being investigated in different populations
around the world[27-36] with different cutoff levels
recommended in different populations dependent on the
intended use of the BCO test. These include: assessing
antenatal smoking[15,16,36]; clinical or community sur-
veys[17,22,27-29,32,33,37]; validating smoking cessation
[18,20,30]; assessing passive smoking[17] or environ-
mental pollution[35]; or investigating sociocultural pat-
terns of smoking[23]. There is, however, no guidance
for the optimum BCO cutoff level to validate self-
reported tobacco smoking in community-based surveys
in Indigenous Australian populations.
This paper examines the sensitivity and specificity of
the BCO test and the optimal cutoff level to distinguish
between smokers and nonsmokers in three remote Indi-
genous populations.
Methods
Setting
The study was conducted in three Arnhem Land com-
munities with a combined Indigenous population of
3,770, including 1,104 males and 1,215 females aged ≥16
years. Contemporary life is strongly influenced by tradi-
tional social and cultural norms and practices, with
more than 20 tribal groups and seven major language
groups represented across the three communities[38].
English is a second or third language[39]. Tobacco was
introduced in the 17th century by Macassan traders
from the Indonesian archipelago, and extended with the
expansion of the pastoral industry and Christian mis-
sions during the early 20th century[40].
Sampling
Between July 2008 and February 2009, 400 Indigenous
people (aged ≥16), comprising 15% of the targeted
population, were interviewed in the baseline phase of a
community-based intervention study.
Local community members were employed as research
workers to assist in the recruitment of participants, to
interpret when local language was required, and to assist
with BCO testing. Given that random sampling is
impractical and intrusive in these communities[41],
participants were opportunistically invited to participate
using quotas to reflect age and gender balances. Inter-
views occurred in public spaces or in people’s homes.
Community Survey: Self-reported tobacco smoking and
BCO
Using a structured questionnaire, participants were
asked about smoking status, smoking history, and pat-
tern of tobacco use. Interviews were conducted by
authors DM, JR, and AC, in most cases with local
research workers. Participants were asked: “Do you
smoke tobacco?” If the participant answered yes, a series
of questions including the type of tobacco product used,
the amount used, when/how the participant started
smoking, and time since last cigarette were asked. Parti-
cipants were also asked if they chewed tobacco, smoked
tobacco in a pipe, or smoked “tailor made” and/or “roll
your own: cigarettes.
Where required, research workers from the local com-
munity were able to provide a personal assessment of
study participants’ smoking status[41], a feasible indica-
tor given sharing tobacco is an integral component of
the collective social fabric of community life[42].
BCO was measured at interview using a hand-held
Bedfont piCO+ Smokerlyzer (Bedfont Scientific, UK,
http://www.bedfont.com). Participants were requested to
inhale and hold their breath for 15 seconds before
exhaling into the analyzer. A BCO cutoff of ≥7 ppm was
used as recommended by the manufacturer. The BCO
analyzers used in the study were calibrated by the man-
ufacturer in May 2008 before the survey commenced
and recalibrated by DM, according to the manufacturer’s
specifications, in November 2008. In trials of survey
procedures, the acceptability of using a portable BCO
analyzer with this population proved to be high. During
the study, it was the experience of DM, JR, and AC that
using the BCO analyser attracted participants into the
study. The immediate return of BCO results provided
an opportunity for participants to actively engage in dis-
cussion about tobacco smoking and have direct benefit
from participating.
Data analysis and approvals
Data were included in the analysis if: (i) self-reported
smokers reported smoking tobacco within the preceding
24 hours; or (ii) self-reported nonsmokers reported
never smoking tobacco or not smoking tobacco for ≥6
months[43]. Given the short half-life of BCO, data from
self-reported occasional tobacco smokers who reported
last smoking tobacco greater than 24 hours previously
were not included in the analysis.
Self-reported smoking and BCO level were analyzed
descriptively using sensitivity and specificity percentages
and a Receiver Operating Characteristics (ROC) analysis.
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Sensitivity was defined as the proportion of all self-
reported smokers for whom there was a positive BCO
test, i.e., a BCO level at or above cutoff (≥7 ppm). Speci-
ficity was the proportion of nonsmokers for whom there
was a negative BCO test, i.e., a BCO level below cutoff
point (<7 ppm). Since a test should ideally have high
sensitivity and high specificity, the average of sensitivity
plus specificity was calculated for different cutoff points
to find the highest level.
Ethics approval for the study was provided by the
Human Research Ethics Committee of James Cook Uni-
versity (approval number H 3072) and the NT Depart-
ment of Health and Families and Menzies School of
Health Research (approval number 0707).
Results
Among the 400 people interviewed, 300 (75%) reported
they smoked tobacco, and 100 (25%) reported they did
not. Four of the 400 interviewed explicitly refused a
BCO test, and 19 were in such poor health that a BCO
test would have been unnecessarily intrusive. BCO was
not tested in a further 57 people interviewed primarily
because they had no time to take the BCO test (n = 40)
or because a BCO analyzer was not available at the time
of interview (n = 17). The remaining 320 people who
provided both a BCO test and information about their
tobacco use included 260 who self-reported they
smoked tobacco and 60 people who self-reported they
did not smoke tobacco. Eleven of the 260 were occa-
sional tobacco smokers and reported they had not
smoked within the preceding 24 hours. In accordance
with inclusion criteria, these 11 occasional smokers were
not included in the analysis. Therefore, BCO tests for
249 self-reported smokers and 60 self-reported nonsmo-
kers were analyzed. The proportions of self-reported
smokers (81% = 249/309) and nonsmokers (19% = 60/
309) in this subsample were similar to proportions of
self-reported smokers (75%) and nonsmokers (25%) in
the sample overall (|z| = 1.90, P = 0.057).
Sensitivity and Specificity
Of the 249 self-reported smokers, 10 had BCO below
the cutoff of ≥7 ppm (96.0% sensitivity), and of the 60
self-reported nonsmokers, four had BCO ≥7 ppm (93.3%
specificity) (Table 1).
Of the four self-reported nonsmokers with BCO ≥7
ppm, three were males, two of whom stated they did
not smoke tobacco but smoked cannabis (BCO 8 ppm
and 33 ppm) (Figure 1). The third male (BCO 14 ppm)
provided no comment, but local research workers later
suggested that he smoked cannabis (Figure 1). One self-
reported female nonsmoker with BCO ≥7 ppm (BCO 9
ppm, Figure 1) provided no further detail at interview,
and local research workers were not present at interview
to assist in clarifying the discrepancy.
Nine of the 10 self-reported smokers with BCO level
<7 ppm provided information about time since last
cigarette. Five reported their last cigarette was smoked
approximately 8-12 hours prior (including three whose
last cigarette was smoked the previous evening). Two
had smoked approximately six hours prior, and two had
their last cigarette within two hours before testing (data
not shown).
Table 2 shows changes in sensitivity and specificity at
different BCO cut-offs. The highest average for the com-
bined sensitivity and specificity (96%) occurs at BCO
cutoffs of ≥5 ppm and ≥6 ppm (Table 2).
Alternative Cut-off Level
If a cutoff level of ≥5 ppm had been used in the study,
the number of false negative tests in self-reported smo-
kers would have been reduced by nine from 10 to 1, a
reduction in the proportion of negative tests from 15%
to 2%. Using a BCO cutoff of ≥ 5 ppm would substan-
tially increase the sensitivity in the study from 96.0% to
99.6% with no change in specificity (93.3%) (Table 2).
However excluding data for the two male cannabis users
who said they did not smoke tobacco from analysis
increased specificity to 96.6% (data not shown).
An ROC analysis was performed to assess the diagnos-
tic accuracy of BCO across the range of possible cutoff
values (Figure 2). The significant contribution to the
area under the curve (AUC = 0.972, P < 0.001) at a
BCO cutoff of ≥5 ppm indicates the considerable power
the BCO marker holds to discriminate between smokers
and nonsmokers in this population. With the data for
the two male self-reported cannabis smokers excluded
from the ROC analysis, the area under the curve at a
BCO cutoff of ≥5 ppm increased marginally to AUC =
0.989. For prevalence estimates in the sample, a cutoff
level of ≥7 ppm would have estimated a prevalence of
79% of smokers. Using a cutoff level of ≥5 ppm would
have estimated a prevalence of 82% of smokers. With
data for the two male cannabis smokers excluded, using
a cutoff level of ≥5 ppm would have estimated tobacco
smoking prevalence of 81%, the proportion of self-
reported smokers in the sample of 400 people inter-
viewed in the study overall.
Discussion
These findings indicate that BCO can be effectively used
to validate self-reported smoking in remote Australian
Indigenous communities. The strong agreement between
self-reported smoking and BCO indicates that self-
reported smoking can be considered a reliable measure
in this population.
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Limitations of the study include that the sample was
not randomly selected and so results cannot be general-
ized. However, participants were recruited to reflect
each community’s age and gender characteristics.
Although BCO was not tested in all participants, the
gender composition and proportions of self-reported
smokers among those who provided a BCO test were
similar to the sample overall. Confidence in the results
is further reinforced by the high level of agreement
between BCO and self-report, by the similarly high
smoking rates found in other studies in the region, and
because community members themselves informed
researchers that results reflected their own family and
community experience.
The community-based survey method recorded self-
reported smoking status and immediately returned BCO
test results to study participants. This allowed discre-
pancies between self-report and BCO to be investigated
at the time of interview with further questions about
smoking history or pattern of use, which assisted in
refining the data.
Ten (4%) self-reported smokers had BCO below the
≥7 ppm cutoff. In nine of these, the self-reported time
since last cigarette was between 2 and 12 hours prior to
BCO test. Three of these nine had not smoked since the
previous evening. Given that BCO has a half-life of
between 3 and 4 hours and can decline by 2.1 to 7.5
ppm per hour, depending on the initial BCO level[44],
Table 1 Breath carbon monoxide (BCO) and self-reported smoking status
BCO level (p.p.m.) Self-reported non-smokers (n) Self-reported smokers (n) in BCO range Total (n)
0-5 p.p.m. 6-10 p.p.m. 11-15 p.p.m. >15 p.p.m.
1 22 22
2 20 1 21
3 11 11
4 3 3
5 2 2
6 7 7
≥7 4 42 66 131 243
Total 309
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Figure 1 Bar chart for breath carbon monoxide (BCO) measurements for self-reported nonsmokers and smokers. The two lines indicate
the cutoffs of ≥7 ppm and ≥5 ppm.
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there was sufficient time for BCO to decline below the
cutoff. Smokers consistently reported periods of heavy
and light smoking with a greater amount of tobacco
smoked in the first few days after fortnightly paydays.
Similar to smoking patterns documented in other Indi-
genous communities[42], the majority of participants
reported regularly running out and frequently requesting
tobacco from family and friends. This provides a plausi-
ble explanation for self-reported tobacco smokers who
only smoke occasionally and/or have low BCO.
Although those who smoke few cigarettes per day can
also have normal BCO[21,23,44], lapsed time since last
cigarette, independent of the number of cigarettes
smoked, accounted for most self-reported smokers with
low BCO in this study.
The study also documented four (7%) self-reported
nonsmokers with BCO ≥7 ppm. While such discrepan-
cies may allude to false self-report or exposure to sec-
ondhand smoke, two of these four results could be
accounted for by cannabis use. It is possible that expo-
sure to secondhand smoke contributed to the small
number of false positives in this study, however cannabis
use in this population is likely to be an important factor.
Studies of cannabis use in similar communities in the
same region indicate that most cannabis users (94%)
blend cannabis with tobacco and smoke the mixture in
handmade “bucket bongs,” with tobacco smokers about
19 times more likely than nonsmokers to also smoke
cannabis[45]. Given that up to two-thirds of males and
half of females regularly use cannabis in the region’s
communities[45,46], cannabis use should be considered
where self-reported nonsmokers show high BCO in
further self-reported smoking validation studies. The
present study did not systematically collect data about
cannabis use at interview. A study investigating both
Table 2 Sensitivity and specificity of various breath
carbon monoxide (BCO) cutoff levels
CO cut-off ≥
(p.p.m.)
Sensitivity Specificity (Sensitivity + specificity)/2
1 1.000 0.000 0.50
2 1.000 0.367 0.68
3 0.996 0.700 0.85
4 0.996 0.883 0.94
5 0.996 0.933 0.96
6 0.988 0.933 0.96
7 0.960 0.933 0.95
8 0.912 0.933 0.92
9 0.888 0.950 0.92
10 0.855 0.967 0.91
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Figure 2 For receiver operating characteristic (ROC) analysis, using data for all participants, 1-specificity (x-axis) was plotted against
sensitivity at breath carbon monoxide (BCO) cutoff levels from 1 ppm to 10 ppm. The numbers placed along the ROC curve indicate BCO
cutoff levels.
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tobacco and cannabis smoking requires a different
approach, including suitable protocols designed to mini-
mize the ethical and legal risks of studying illegal beha-
viors in these disadvantaged and disempowered
populations in Australia[45].
Only a few studies in Indigenous Australian popula-
tions have used biomarkers to verify self-reported smok-
ing. A community-based study in an urban population
recorded 10% of self-reported nonsmokers with BCO
above cutoff of 9 ppm[26], while a clinic-based study in
a remote population tested BCO but did not analyze
discrepancies[25]. Two clinic-based studies using urine
cotinine, one remote and one urban, both found higher
discrepancies. The remote study found 15% of self-
reported nonsmokers produced levels above cutoff (539
nmom/l)[7], while the urban study found 17% of self-
reported nonsmoking pregnant women produced levels
above cutoff (250 ng/ml)[14]. In the study reported
here, 7% of self-reported nonsmokers had BCO above
cutoff (≥7 ppm). Caution is, however, required before
making direct comparison between these studies given
the different population groups, recruitment methods,
sample size, biomarkers, and study context.
A range of BCO cutoff levels has been used to validate
self-reported smoking in different population groups
around the world. Cutoffs as high as 10 ppm have been
used[20,47,48]. Others have used 9 ppm[22,26,37,44]; 8
ppm[19]; 7 ppm[28]; 6.5 ppm[17]; or 6 ppm[21]. Several
studies recommend cutoffs as low as 2 to 3 ppm
[29,31,36]. However, self-reported smoking status and
BCO level can vary between ethnic groups in the same
location[23]. This suggests possible cultural or commu-
nication differences in responses to questions about
smoking, a challenge well-known in remote Aboriginal
communities[7,39]. Different sociocultural patterns of
smoking may mean different BCO cutoffs are required
in different populations. In this study population, redu-
cing the BCO cutoff from ≥7 ppm to ≥5 ppm would
increase the self-reported smokers verified from 96.0%
to 99.6%, while self-reported nonsmokers verified would
remain unchanged at 93.3%. With better information in
future studies about those who smoke cannabis and not
tobacco in these communities, the proportion of self-
reported nonsmokers of tobacco verified could be as
high as 96.6%.
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